Immune therapy have shown new and exciting perspectives for cancer treatment. Aim of our
study was to evaluate toxicity and possible adverse effects from vaccination of patients with …

Purpose: We evaluated the clinical benefit of an allogeneic melanoma cell lysate (MCL)–
pulsed autologous dendritic cell (DC) vaccine in advanced colorectal cancer patients …

Dendritic cells (DCs) are professional antigen‐presenting cells (APCs) that can be used for
vaccination purposes, to induce a specific T‐cell response in vivo against melanoma …

Patients with disseminated colorectal cancer have a poor prognosis. Preliminary studies
have shown encouraging results from vaccines based on dendritic cells. The aim of this …

We performed continuous dendritic cells (DCs) vaccination to treat a patient with
chemotherapy-resistant recurrent rectal carcinoma and lung and bone metastases. A patient …

Results Flow cytometry confirmed dendritic cell phenotype and in vitro function was
confirmed by mixed lymphocyte reaction. No major adverse effects were observed. Eleven of …

Purpose: Dendritic cell (DC)-based immunotherapy is rapidly emerging as a viable tool in
cancer treatment. This approach has been used mostly in patients in the presence of defined …

We conducted a pilot study to assess the feasibility and efficacy of immunotherapy for stage
IV malignant melanoma patients resistant to conventional therapies involving vaccination …

Background To better evaluate and improve the efficacy of dendritic cell (DC)-based cancer
immunotherapy, we conducted a clinical study of patients with advanced colorectal cancer …

Abstract Between January 2001 and September 2007, we treated 54 metastatic melanoma
patients with patient-specific tumor cell vaccines consisting of dendritic cells (DCS), derived …